X

Surya Pharmaceutical Ltd Stock Analysis

Small Cap
Evaluated by 204 users | BSE: 532516 | NSE: SURYAPHARM |
Pharmaceuticals & Drugs
Surya Pharmaceutical incorporated in 1992, is engaged in manufacturing of active pharmaceutical ingredients (API's), finished drug formulations (FDF's), fine intermediates, herbal products, and mint/menthol derivatives. The company has client based in over 90 countries across the globe.The...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13
Return on Capital Employed 13.11%13.56%16.34%12.16%14.44%14.22%13.53%11.78%-5.97%-6.71%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 1621692392834877231,1341,6001,62360.3
Y-o-Y Gr. Rt.-4.3%41.2%18.8%71.7%48.6%56.9%41.1%1.4%-96.3%
Adjusted EPS (Rs.) 0.570.791.921.642.884.045.135.17-12-13.69
Y-o-Y Gr. Rt.-38.6%143%-14.6%75.6%40.3%27%0.8%-332.1%NA
Book Value per Share (Rs.) 5.286.128.129.5112.2915.8520.8126.6312.21-2.68
Adjusted Net Profit 68.421.323.741.758.574.299.7-243-278
Net Op. Cash Flow (Rs. Cr.) 2.42.524.510.567.8-8.116568.9386166
Debt to Cash Flow from Ops 20.9626.646.0418.574.69-61.824.2820.914.5512.14
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Surya Pharmaceutical Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -10.4%-34.1%-62.4%-96.3%
Adjusted EPS -242.4%-236.6%-238.7%NA
Book Value per Share -192.7-173.7-150.5-122
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'04Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13
Return on Equity (%) 12.7813.325.8220.2426.3428.6227.8324.22-63.41-287.37
Operating Profit Margin (%) 1417.7319.6818.3417.816.6114.3616.4-8.75-257.57
Net Profit Margin (%) 3.714.978.948.358.578.096.546.23-14.99-460.01
Debt to Equity 0.921.031.641.421.792.182.352.817.09-36.98
Working Capital Days 1802181982382272512482713036,544
Cash Conversion Cycle 741081101521321231261962515,318
Entity Percentage Holding
Promoters 0.96%
Institutions 0.02%
Non-Institutions 99.01%
Pledged *97.2897.2897.2897.2896.7495.7878.8771.6726.1826.18
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Surya Pharmaceutical incorporated in 1992, is engaged in manufacturing of active pharmaceutical ingredients (API's), finished drug formulations (FDF's), fine intermediates, herbal products, and mint/menthol derivatives. The company has client based in over 90 countries across the globe.

The company has received ISO 9001-2000 certifications for its quality management. The company is listed on the Bombay Stock Exchange and the National Stock Exchange. The company has employee strength of

Surya Pharmaceutical incorporated in 1992, is engaged in manufacturing of active pharmaceutical ingredients (API's), finished drug formulations (FDF's), fine intermediates, herbal products, and mint/menthol derivatives. The company has client based in over 90 countries across the globe.

The company has received ISO 9001-2000 certifications for its quality management. The company is listed on the Bombay Stock Exchange and the National Stock Exchange. The company has employee strength of more than 2000 people. Company offices located at Shanghai, Singapore, Europe and the United States of America (USA).

Company has production capacity of 600 million of capsules and tablets each per annum.

Products

Intermediates- Under this company manufactures Cefuroxime Acid, Cefaclor and many more.

API-Company has annual capacity of 2500MT of API under which it produces Ampicillin Trihydrat, Cloxacillin Sodium, Flucloxacillin Sodium, Cefprozil, Cefpodoxime Proxetil, Bacampicillin Hydrochloride, Oxacillin Sodium, Cefuroxime Axetil and many more.

Menthol- Under this company manufactures Menthol Powder, Menthol Crystals, Menthol Flakes, Essential Oil, Basil Oil, Dementholised Peppermint Oil, Natural Mint Terpenes, CIS-3-Hexenol, Menthones, Mentha Piperita Oil, Spearmint Oil and Menthyl Lactate. Company has annual production capacity of 4500 MT of Menthol Powder, 3600 MT of Menthol Crystals and 2800 MT of Dementholised Pepermint oil.

Herbal Products- Company manufactures products such as Quinine Sulphate, Quinine Hydrochloride, Colchicine, Thiocolchicoside, Raubasine, 5-HTP and 10-DAB III.

Company also conduct contract manufacturing for various companies.

Recent DevelopmentSurya Pharmaceutical plans to establish 500 healthcare and pharma retail stores in the next three years at an investment of Rs.250 crore. By March 2010, company would open 100 stores in the NCR (national capital region).

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback